Wall Street brokerages expect X4 Pharmaceuticals Inc (NASDAQ:XFOR) to report earnings per share (EPS) of ($0.79) for the current quarter, according to Zacks. Zero analysts have issued estimates for X4 Pharmaceuticals’ earnings. X4 Pharmaceuticals reported earnings per share of ($5.10) during the same quarter last year, which suggests a positive year-over-year growth rate of 84.5%. The company is expected to announce its next earnings report on Monday, August 12th.
On average, analysts expect that X4 Pharmaceuticals will report full year earnings of ($3.77) per share for the current fiscal year, with EPS estimates ranging from ($3.90) to ($3.64). For the next financial year, analysts expect that the company will post earnings of ($3.80) per share, with EPS estimates ranging from ($3.84) to ($3.75). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for X4 Pharmaceuticals.
X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($6.67) earnings per share for the quarter.
Shares of XFOR stock traded up $0.01 during trading hours on Thursday, hitting $14.41. 18,900 shares of the company were exchanged, compared to its average volume of 39,728. X4 Pharmaceuticals has a 1 year low of $6.90 and a 1 year high of $113.94. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.57.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Read More: Why are percentage gainers important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.